Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Classificação em ações #27036
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Preço da ação
$1.48
Última sincronização: 2023-05-31
Valor de mercado
$35.54M
Variação (1 dia)
-5.73%
Variação (1 ano)
0.00%
País
US
Negociar TCR2 Therapeutics Inc. (TCRR)

Categoria

Histórico de rendimento de dividendos para TCR2 Therapeutics Inc. (TCRR)
O rendimento de dividendos (TTM) da TCR2 Therapeutics Inc. (símbolo da ação: TCRR) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para TCR2 Therapeutics Inc. (TCRR) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
Não há dados suficientes para as datas fornecidas.
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH